<DOC>
	<DOCNO>NCT01800006</DOCNO>
	<brief_summary>This international study prospective noninterventional observational cohort study patient non-valvular atrial fibrillation prescribe rivaroxaban routine treatment condition prevent stroke non-central nervous system systemic embolism . Patients follow 1 year 30 day end rivaroxaban therapy case therapy discontinue earlier 12 month . Serious adverse event follow adequately . Laboratory value ( e.g. , Hb , HCT , haemoccult ) document point time measure .</brief_summary>
	<brief_title>Xarelto Prevention Stroke Patients With Atrial Fibrillation Latinamerica EMEA Region</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Female male patient â‰¥ 18 year age diagnosis nonvalvular atrial fibrillation start treatment rivaroxaban prevent stroke nonCNS systemic embolism , consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Observation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Embolism</keyword>
</DOC>